PerkinElmer Stock

$89.67

2.21% yesterday

NYSE, Aug 21, 10:00 pm CET

ISIN

US7140461093

Symbol

RVTY

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

PerkinElmer Stock price

$89.67

-27.23 23.29% 5Y

NYSE, Closing price Thu, Aug 21 2025

-2.03 2.21%

ISIN

US7140461093

Symbol

RVTY

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$10.6b

Enterprise Value

$12.9b

Net debt

$2.2b

Cash

$991.9m

Shares outstanding

116.3m

Valuation (TTM | estimate)

P/E

37.9 | 18.2

P/S

3.8 | 3.7

EV/Sales

4.6 | 4.4

EV/FCF

25.6

P/B

1.4

Dividends

DPS

$0.28

Yield 1Y | 5Y

0.3% | 0.2%

Growth 1Y | 5Y

0.0% | 0.0%

Payout 1Y | 3Y

12.7% | 6.9%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$2.8b | $2.9b

EBITDA

$812.7m | $873.7m

EBIT

$399.8m | $792.1m

Net Income

$285.2m | $585.2m

Free Cash Flow

$503.0m

Growth (TTM | estimate)

Revenue

3.3% | 5.6%

EBITDA

1.9% | 2.9%

EBIT

8.4% | 88.1%

Net Income

68.3% | 116.4%

Free Cash Flow

31.3%

Financial Health

Equity Ratio

61.9%

Return on Equity

3.5%

ROCE

3.4%

ROIC

Debt/Equity

0.4

EPS

$2.4

FCF per Share

$4.3

Short interest

7.3%

Employees

11k

Rev per Employee

$250.0k

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Get Started for Free Today

PerkinElmer Stock Analysis

Unlock Scores for Free

??

26 Analysts have issued a PerkinElmer forecast:

17x Buy

65%

8x Hold

31%

More details on Analyst Estimates Including Price Targets

26 Analysts have issued a PerkinElmer forecast:

Buy

65%

Hold

31%

Sell

Analyst Estimates with Stock Price Targets

Financial data from PerkinElmer

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	2,798 2,798	3% 3% 100%
- Direct Costs	1,233 1,233	2% 2% 44%
Gross Profit	1,565 1,565	5% 5% 56%
- Selling and Administrative Expenses	965 965	5% 5% 34%
- Research and Development Expense	205 205	2% 2% 7%
EBITDA	813 813	2% 2% 29%
- Depreciation and Amortization	413 413	4% 4% 15%
EBIT (Operating Income) EBIT	400 400	8% 8% 14%
Net Profit	285 285	68% 68% 10%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

PerkinElmer Stock News

Neutral

Business Wire

●

4 days ago

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference Wednesday, September 3, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2025 Baird Global Healthcare Conference Tuesday, September 9, 2025 2:35 p.m. ET – Steve Willoughby, senior vice presi...

Neutral

Business Wire

●

16 days ago

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalab...

Neutral

Seeking Alpha

●

24 days ago

Revvity Q2: Headwinds From China And Customers, Buy On Weakness

Revvity, Inc.'s focus on high-growth markets like cell and gene therapies and precision medicine positions it for long-term expansion despite near-term challenges. The recent divestiture streamlines Revvity's portfolio, allowing greater investment in specialized diagnostics and software, which are expected to drive future growth. While facing weak academic/government demand and China headwinds,...

More PerkinElmer News

Company Profile

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.

Head office	United States
CEO	Prahlad Singh
Employees	11,000
Founded	1937
Website	www.revvity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now